Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.

Article Details

Citation
Copy to clipboard

Gera S, Musch E, Osterheld HK, Loos U

Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.

Cancer Chemother Pharmacol. 1989;23(2):76-80. doi: 10.1007/BF00273521.

PubMed ID
2910515 [ View in PubMed
]
Abstract

Experiments to determine the hydrolysis and protein binding of melphalan (L-phenylalanine mustard, L-PAM) were carried out in vitro for therapeutic concentration of the drug: the decrease in L-PAM concentration in plasma and whole blood during 24 h incubation at 37 degrees C was only 5% due to hydrolysis. Serum protein binding was about 90%, whereby 60% and 20% of this binding was due to interactions with albumin and acid alpha 1-glycoprotein, respectively. Immunoglobulins did not participate in the binding of L-PAM. The covalently bound part of L-PAM in serum was 30% in the concentration range of 1-30 micrograms/ml. The binding of dihydroxymelphalan (DOH) in serum did not exceed 20%. Glucocorticoids used in combination with L-PAM for treating multiple myeloma did not influence its protein binding. Our study with 35 sera from 15 patients with multiple myeloma shows that high levels of paraproteins do not increase but may decrease the binding of L-PAM, resulting in an elevated concentration of free drug.

DrugBank Data that Cites this Article

Drugs